Hudson Bay Capital Management LP Buys New Position in Ascendis Pharma A/S $ASND

Hudson Bay Capital Management LP purchased a new position in Ascendis Pharma A/S (NASDAQ:ASND) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 78,934 shares of the biotechnology company’s stock, valued at approximately $15,693,000. Hudson Bay Capital Management LP owned 0.13% of Ascendis Pharma A/S as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Rhumbline Advisers raised its stake in shares of Ascendis Pharma A/S by 4.0% during the second quarter. Rhumbline Advisers now owns 1,441 shares of the biotechnology company’s stock valued at $249,000 after purchasing an additional 55 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Ascendis Pharma A/S by 1.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,081 shares of the biotechnology company’s stock valued at $1,209,000 after purchasing an additional 58 shares during the period. China Universal Asset Management Co. Ltd. boosted its stake in shares of Ascendis Pharma A/S by 0.6% in the second quarter. China Universal Asset Management Co. Ltd. now owns 12,186 shares of the biotechnology company’s stock valued at $2,103,000 after purchasing an additional 73 shares during the period. Jones Financial Companies Lllp grew its holdings in Ascendis Pharma A/S by 57.2% during the 3rd quarter. Jones Financial Companies Lllp now owns 228 shares of the biotechnology company’s stock valued at $44,000 after purchasing an additional 83 shares in the last quarter. Finally, Main Management ETF Advisors LLC grew its holdings in Ascendis Pharma A/S by 1.7% during the 2nd quarter. Main Management ETF Advisors LLC now owns 5,864 shares of the biotechnology company’s stock valued at $1,012,000 after purchasing an additional 96 shares in the last quarter.

Ascendis Pharma A/S Price Performance

Shares of ASND stock opened at $223.38 on Friday. The firm has a fifty day moving average of $225.55 and a two-hundred day moving average of $212.02. The firm has a market cap of $13.85 billion, a P/E ratio of -50.77 and a beta of 0.43. Ascendis Pharma A/S has a 1-year low of $124.06 and a 1-year high of $248.60.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its earnings results on Wednesday, February 11th. The biotechnology company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.58). The firm had revenue of $290.38 million for the quarter, compared to analyst estimates of $285.35 million. On average, sell-side analysts expect that Ascendis Pharma A/S will post -4.34 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on ASND shares. Bank of America reiterated a “buy” rating and issued a $262.00 price objective on shares of Ascendis Pharma A/S in a report on Thursday, March 5th. Stifel Nicolaus set a $332.00 target price on Ascendis Pharma A/S in a research note on Wednesday, March 4th. Wedbush lifted their target price on Ascendis Pharma A/S from $240.00 to $273.00 and gave the stock an “outperform” rating in a research report on Thursday, February 12th. Evercore reiterated an “outperform” rating and issued a $324.00 price target on shares of Ascendis Pharma A/S in a research note on Monday, March 2nd. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $300.00 price target on shares of Ascendis Pharma A/S in a report on Monday, March 2nd. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $289.89.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.